Cytokinetics (CYTK) Files Form 144 for 4,300-Share Sale via Morgan Stanley

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) filed a Form 144 notifying a proposed sale of 4,300 common shares, estimated at an aggregate market value of $151,919.00, to be executed approximately on 09/02/2025 on NASDAQ. The securities were acquired as restricted stock units (RSUs) on 01/02/2024 and the filing indicates the broker handling the transaction is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states there were 119,657,156 shares outstanding for the class reported. No securities of the issuer were reported sold by the reporting person in the prior three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Positive

• Compliance and transparency: The filing clearly discloses the proposed sale details, broker, acquisition type, and required attestation.
• Limited size relative to outstanding shares: 4,300 shares versus 119,657,156 outstanding suggests the sale is immaterial to overall capitalization.

Negative

• Insider liquidity event: The reporting person intends to sell shares acquired as RSUs, which investors may note as insider selling activity.

Insights

Securities Analyst

TL;DR: Routine insider sale notice; small position relative to total shares outstanding, informational for liquidity and insider activity tracking.

The Form 144 documents a proposed sale of 4,300 common shares acquired as RSUs on 01/02/2024, with an aggregate market value of $151,919 and an approximate sale date of 09/02/2025. This is a standard compliance filing under Rule 144 identifying the broker and sale details. Relative to the reported 119,657,156 shares outstanding, the quantity is immaterial in size, suggesting limited direct market impact. The filing confirms no other sales in the prior three months and includes the required representation about absence of undisclosed material adverse information.

Corporate Governance Specialist

TL;DR: Filing meets disclosure requirements; provides transparency on executive/insider liquidity but contains no indication of material corporate events.

The notice specifies the nature of acquisition (Restricted Stock Units) and identifies the broker facilitating the sale, which aligns with standard insider selling disclosures and Rule 144 procedures. The presence of the seller's certification regarding material information is the expected attestation. There are no statements in the filing indicating material transactions beyond the single proposed sale or any corporate governance actions tied to the sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4300	151919.00	119657156	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/02/2024	Restricted Stock Units	Issuer			4300	01/02/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Cytokinetics (CYTK) disclose in this Form 144?

The filing notifies a proposed sale of 4,300 common shares (acquired as RSUs on 01/02/2024) with an aggregate market value of $151,919.00, to be sold about 09/02/2025 on NASDAQ via Morgan Stanley Smith Barney LLC.

Who is the broker handling the proposed sale for CYTK?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

How many CYTK shares are outstanding according to the Form 144?

The filing reports 119,657,156 shares outstanding for the class reported.

Were any CYTK securities sold by the reporting person in the past three months?

The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

What was the acquisition method and date for the securities to be sold?

The securities were acquired as Restricted Stock Units on 01/02/2024, with full payment/settlement indicated on the same date.